Pieris Pharmaceuticals Shares Outstanding 2014-2021 | PIRS

Pieris Pharmaceuticals shares outstanding from 2014 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Pieris Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 54
2019 51
2018 53
2017 44
2016 42
2015 34
2014 14
2013 12
Pieris Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 68
2021-06-30 62
2021-03-31 56
2020-12-31 54
2020-09-30 54
2020-06-30 52
2020-03-31 55
2019-12-31 51
2019-09-30 49
2019-06-30 49
2019-03-31 51
2018-12-31 53
2018-09-30 54
2018-06-30 54
2018-03-31 50
2017-12-31 44
2017-09-30 44
2017-06-30 43
2017-03-31 43
2016-12-31 42
2016-09-30 43
2016-06-30 41
2016-03-31 40
2015-12-31 34
2015-09-30 39
2015-06-30 29
2015-03-31 29
2014-12-31 20
2014-09-30 12
2014-06-30 12
2014-03-31 12
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.251B $0.029B
Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75